Lay summary
Severe pneumonia is a major cause of death and disability in Aotearoa. The best way to treat severe pneumonia remains unclear. For specific infections, such as COVID-19, the REMAP-CAP study identified treatments that improve short and long-term outcomes. It is unclear whether these treatments are effective in cases of pneumonia caused by other viruses or bacteria. This proposed research builds on what was learned about novel clinical trial designs during the pandemic and expands the REMAP-CAP trial to identify the best treatments for a broader group of patients with pneumonia, such as those with influenza or those admitted to a hospital ward rather than an intensive care unit. The overarching goal of this research is to improve outcomes and reduce inequities for patients hospitalised with severe pneumonia in Aotearoa New Zealand.